KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) Thursday said it has discontinued the Phase 3 KeyVibe-008 study in patients with extensive-stage small cell lung cancer (ES-SCLC), as recommended by an independent Data Monitoring Committee.
The study was evaluating vibostolimab plus pembrolizumab in combination with chemotherapy compared to atezolizumab in combination with chemotherapy, in patients with ES-SCLC. Data from the study showed that the primary endpoint of overall survival met the pre-specified futility criteria.
Additionally, patients in the vibostolimab plus pembrolizumab arm experienced a higher rate of adverse events and immune-related adverse events compared to the other arm.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News
